<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168870</url>
  </required_header>
  <id_info>
    <org_study_id>Haema CBF AHM UK/AS 04</org_study_id>
    <nct_id>NCT00168870</nct_id>
  </id_info>
  <brief_title>Study of Metastatic Ocular Melanoma</brief_title>
  <official_title>Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      This study evaluates treatment with combination versus monotherapy for patients with
      metastatic ocular melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of patients with metastatic ocular melanoma with combination chemotherapy
      Gemcitabine and Treosulfan versus monotherapy with Treosulfan as first-line chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Ocular Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic ocular melanoma

        Exclusion Criteria:

          -  Prior treatment with chemotherapy

          -  Active 2nd malignancy

          -  Cerebral metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Keilholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Campus Benjamin Franklin Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrich Keilholz, MD</last_name>
    <phone>+49-30-8445-3596</phone>
    <email>ulrich.keilholz@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Schmittel, MD</last_name>
    <phone>+49-30-8445-3090</phone>
    <email>alexander.schmittel@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology &amp; Oncology Charité CBF Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Keilholz, MD</last_name>
      <phone>+49-30-8445-3596</phone>
      <email>ulrich.keilholz@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Schmittel, MD</last_name>
      <phone>+49-30-8445-3090</phone>
      <email>alexander.schmittel@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Keilholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>August 30, 2007</last_update_submitted>
  <last_update_submitted_qc>August 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2007</last_update_posted>
  <keyword>metastatic ocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

